L-arginine

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	2025/04/27	NCT06947265	Phase 4	Completed	Fayoum University Hospital
The Role of L-arginine in Polycystic Ovary Syndrome	2024/12/11	NCT06728644	Not Applicable	Completed	Shanghai 10th People's Hospital
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients	2024/05/08	NCT06405243	Phase 3	Not yet recruiting	Beni-Suef University
Association Between Postoperative Administration of L-Arginine and CSA-AKI	2024/02/08	NCT06248359	N/A	Recruiting	Xijing Hospital
Evaluation of the Effect of Liposomal L-Arg and Vit C Integration on Mitochondrial Function in Patients With Heart Failure	2023/09/21	NCT06044194	Phase 3	Recruiting	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.	2023/07/06	NCT05932979	Phase 2	Withdrawn	Centro Universitario de Tonalá
L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity	2022/07/22	NCT05470998	Phase 3	Recruiting	Tanta University
Immunonutrition for Diabetic Foot Ulcers	2022/03/16	NCT05281562	Phase 2	Terminated	Prisma Health-Midlands
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial	2021/04/09	NCT04839354	Phase 3	Completed	Claudia R. Morris
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication	2021/03/16	NCT04800692	Phase 1	Recruiting	Louis Messina

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
LysaKare	Advanced Accelerator Applications,Advanced Accelerator Applications,8-10 Rue Henri Sainte-Claire Deville,92500 Rueil-Malmaison,France	Authorised	7/25/2019
LysaKare	Advanced Accelerator Applications,Advanced Accelerator Applications,8-10 Rue Henri Sainte-Claire Deville,92500 Rueil-Malmaison,France	Authorised	7/25/2019

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
SYNTHAMIN 17 WITHOUT ELECTROLYTES 10% AMINO ACID INTRAVENOUS INFUSION	BAXTER HEALTHCARE LTD	SIN09992P	INJECTION	11.50 g/l	9/15/1998
LYSAKARE SOLUTION FOR INFUSION 25G / 25G	LABORATOIRE BIOLUZ	SIN16003P	INFUSION, SOLUTION	25 g/L	8/31/2020
PRIMENE 10% AMINO ACID INTRAVENOUS INFUSION	BIEFFE MEDITAL S.P.A.	SIN10252P	INJECTION	8.4 g/l	9/23/1998
AMINOVEN SOLUTION FOR INFUSION 5%	FRESENIUS KABI AUSTRIA GMBH	SIN11682P	INJECTION	6.000 g/1000 ml	9/25/2001
SMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION	Fresenius Kabi AB, Site Uppsala	SIN16136P	INJECTION, EMULSION	7.9g/1000ml	3/24/2021
NUTRINEAL PD4 WITH 1.1% AMINO ACID SOLUTION	BAXTER HEALTHCARE SA, SINGAPORE BRANCH, BAXTER HEALTHCARE SA	SIN09353P	SOLUTION, STERILE	1.071 g/l	5/27/1997
SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSION	Fresenius Kabi AB, Site Uppsala	SIN16135P	INJECTION, EMULSION	7.9g/1000ml	3/24/2021
KABIVEN EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11657P	INJECTION	3.3 g/1000 ml	9/4/2001
AMINOVEN SOLUTION FOR INFUSION 15%	Fresenius Kabi Austria GmbH (Graz)	SIN16337P	INFUSION, SOLUTION	20g/L	9/30/2021
KABIVEN PERIPHERAL EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11718P	INJECTION	2.4 g/l	11/16/2001

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
VELSIPITY TABLETS 2MG	N/A	Everest Medicines II (HK) Limited	N/A	N/A	4/25/2025

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTRLYTES IN 10% DEXTROSE	baxter corporation clintec nutrition division	N/A	Solution - Intravenous	489 MG / 100 ML	12/31/1996
4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE	baxter corporation clintec nutrition division	N/A	Solution - Intravenous	489 MG / 100 ML	12/31/1996
2.75%TRAVASOL AMINO ACID INJ.W.ELEC.W.5%DEX.	clintec nutrition company	02143240	Liquid - Intravenous	316 MG / 100 ML	12/31/1996
4.25%TRAVASOL AMINO ACID INJ.W.ELECW.5%DEX.	clintec nutrition company	02143224	Liquid - Intravenous	489 MG / 100 ML	12/31/1996
5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE	baxter corporation clintec nutrition division	02142244	Solution - Intravenous	575 MG / 100 ML	12/31/1996
2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX	baxter corporation clintec nutrition division	02013975	Solution - Intravenous	260 MG / 100 ML	12/31/1993
CLINIMIX E	baxter corporation	02013967	Solution - Intravenous	520 MG / 100 ML	12/31/1993
5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE	baxter corporation clintec nutrition division	02142252	Solution - Intravenous	575 MG / 100 ML	12/31/1996
5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE	baxter corporation clintec nutrition division	02142368	Solution - Intravenous	575 MG / 100 ML	12/31/1996
4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE	baxter corporation clintec nutrition division	02142295	Solution - Intravenous	489 MG / 100 ML	12/31/1996

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Novel Fenugreek-Based Nanoparticles Show Promise in Enhancing Diabetes Drug Delivery

8 months ago

Scientists have developed innovative lipid nanoparticles from fenugreek seed oil to enhance the delivery and effectiveness of L-arginine, showing superior antioxidant and anti-inflammatory properties compared to conventional diabetes treatments.

L-Arginine Shows Promise but Falls Short of Statistical Significance in Spinocerebellar Ataxia Type 6 Trial

a year ago

A Phase 2 trial of L-arginine in Spinocerebellar Ataxia type 6 (SCA6) showed a trend toward symptom improvement, but the results did not reach statistical significance.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access